vimarsana.com
  1. Home
  2. Live Updates
  3. Accelerated Approval Program - Breaking News

Page 9 - Accelerated Approval Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Novartis Scemblix®, with novel mechanism of action, approved by the European Commission for adult patients with chronic myeloid leukemia | Small Molecules

Novartis Scemblix®, with novel mechanism of action, approved by the European Commission for adult patients with chronic myeloid leukemia

United statesUnited kingdomEast hanoverNovartis scemblixHaseeb ahmadAndreas hochhausOncology at jena university hospitalAmerican society for clinical oncologyEuropean hematology associationEuropean commissionHead of the department hematologyApproval programEuropean unionEuropean medicines agencyNovartis pharmaceuticals corpCommittee for medicinal products human use

Stock Market | Daily Herald

Stock Market | Daily Herald
dailyherald.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailyherald.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomGreat britainClay siegallRoger danseyDaiichi sankyoTelisotuzumab vedotinChildren oncology group presentedEuropean commission ec approvalUs district courtTrademark officeEuropean unionEuropean union member statesCompany quarterly report on formChildren oncology groupDrug administration

Novartis Pharma AG: Novartis receives positive CHMP opinion for Scemblix, a novel treatment for adult patients with chronic myeloid leukemia

With unique STAMP mechanism of action, Scemblix could provide a new option for patients in Europe with chronic myeloid leukemia (CML) who have suffered intolerance or inadequate response with at least

United statesEast hanoverIsabella zinckHaseeb ahmadAmy wolfNicole zinsli sommFloriana riccio furnariSamir shahParag mahantiJulie masowSloan simpsonAndreas hochhausAlina levchukOncology at jena university hospitalAmerican society for clinical oncologyEuropean hematology association

FDA approves Novartis Tafinlar + Mekinist combination therapy

The US FDA has granted accelerated approval to Novartis’ combination therapy Tafinlar (dabrafenib) + Mekinist (trametinib) to treat solid tumours.

Reshema kemps polancoApproval programPhase ii rare oncology agnostic researchAccelerated approval programOncology agnostic research

Investegate |NOVARTIS AG CHF0 50(REGD) Announcements | NOVARTIS AG CHF0 50(REGD): Novartis Tafinlar + Mekinist receives FDA approval for first tumor-agnostic indication for BRAF V600E solid tumors

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis Tafinlar + Mekinist receives FDA approval for first tumor-agnostic indication for BRAF V600E solid tumors

United statesIsabella zinckVivek subbiahDan connellyNovartis tafinlarNicole zinsli sommSamir shahParag mahantiJulie masowSloan simpsonAlina levchukReshema kemps polancoDivision of cancer medicineUniversity of texas md anderson cancer centerDrug administrationNovartis oncology communications

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.